Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102082 · ClinicalTrials.gov registry record · NA
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand
A NA study of Smoking Behaviors, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07102082: Recruiting NA study of Smoking Behaviors, sponsored by Roswell Park Cancer Institute.
NCT07102082 is a NA study of Smoking Behaviors that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 160 participants, below the 431-participant average among 21 other Smoking Behaviors trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07102082, a NA study of Smoking Behaviors, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
To explore consumer responses to the announcement and implementation of new modified risk claims for Copenhagen and General Snus (brands of smokeless tobacco (ST) products) using a series of complementary and innovative research activities and methods.
Primary Outcome
After watching a series of advertisements for oral smokeless tobacco products, participants will provide opinions of them, including likelihood of buying product.
Conditions Studied
Interventions
- BEHAVIORAL Modified Risk - None
- BEHAVIORAL Modified Risk Claim
Study Locations (1)
New York
- Roswell Park - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT07102082 shows while recruiting
NCT07102082 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 431-participant average among 21 other Smoking Behaviors trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Smoking Behaviors appearing as the primary indexed condition, and to 2 interventions - of which Modified Risk - None is the first listed.
NCT07102082 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07102082 about?
NCT07102082 is a clinical study titled "Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand". To explore consumer responses to the announcement and implementation of new modified risk claims for Copenhagen and General Snus (brands of smokeless tobacco (ST) products) using a series of complementary and innovative research activities and methods.
What is the current status of trial NCT07102082?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2025-09-25. Estimated completion is 2026-11-30.
What conditions does trial NCT07102082 study?
This clinical trial studies the following conditions: Smoking Behaviors.
What interventions are being tested in trial NCT07102082?
The interventions under investigation include: Modified Risk - None (BEHAVIORAL), Modified Risk Claim (BEHAVIORAL).
Who is sponsoring clinical trial NCT07102082?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07102082 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Behaviors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07102082's enrollment target sits among peer trials
160 13th of 21 higher than 9 of 21 other Smoking Behaviors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Behaviors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
RECRUITING · NA
-
Take A Break - Rural
RECRUITING · NA
-
Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction
RECRUITING · NA
-
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
RECRUITING · NA
-
A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI